JP2005512996A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005512996A5 JP2005512996A5 JP2003541817A JP2003541817A JP2005512996A5 JP 2005512996 A5 JP2005512996 A5 JP 2005512996A5 JP 2003541817 A JP2003541817 A JP 2003541817A JP 2003541817 A JP2003541817 A JP 2003541817A JP 2005512996 A5 JP2005512996 A5 JP 2005512996A5
- Authority
- JP
- Japan
- Prior art keywords
- diphenyl compound
- diphenyl
- patient
- chemotherapeutic agent
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 diphenyl compound Chemical class 0.000 claims description 28
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000002494 carbonylidene group Chemical group O=C=* 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims 26
- 239000004305 biphenyl Substances 0.000 claims 26
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 26
- 238000000034 method Methods 0.000 claims 11
- 239000002246 antineoplastic agent Substances 0.000 claims 8
- 229940127089 cytotoxic agent Drugs 0.000 claims 8
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 208000026310 Breast neoplasm Diseases 0.000 claims 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 4
- 125000006267 biphenyl group Chemical group 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 102000015694 estrogen receptors Human genes 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33114201P | 2001-11-09 | 2001-11-09 | |
| US40724102P | 2002-09-03 | 2002-09-03 | |
| PCT/CA2002/001725 WO2003039526A1 (en) | 2001-11-09 | 2002-11-06 | Treatment of breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005512996A JP2005512996A (ja) | 2005-05-12 |
| JP2005512996A5 true JP2005512996A5 (https=) | 2006-01-05 |
Family
ID=26987607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003541817A Withdrawn JP2005512996A (ja) | 2001-11-09 | 2002-11-06 | 乳癌の治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20050119263A1 (https=) |
| EP (1) | EP1441711A1 (https=) |
| JP (1) | JP2005512996A (https=) |
| CA (1) | CA2465916A1 (https=) |
| WO (1) | WO2003039526A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003269621A1 (en) * | 2002-09-03 | 2004-03-29 | Lorne J. Brandes | Neoadjuvant treatment of breast cancer |
| CA2497180A1 (en) * | 2002-09-04 | 2004-03-18 | The University Of Manitoba | Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist |
| CN1703212A (zh) * | 2002-09-11 | 2005-11-30 | 马尼托巴大学 | Dppe与其它化学治疗剂联合治疗乳腺癌的用途 |
| WO2010118782A1 (en) * | 2009-04-17 | 2010-10-21 | Universite Libre De Bruxelles | Methods and tools for predicting the efficiency of anthracyclines in cancer |
| US20110195848A1 (en) * | 2010-01-08 | 2011-08-11 | Roopra Avtar S | Gene expression and breast cancer |
| BR112017015013A2 (pt) | 2015-01-19 | 2018-01-23 | Belina Pharma Ab | anti-histamina para uso no tratamento de câncer da mama |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1229604A (en) * | 1984-02-14 | 1987-11-24 | Lorne J. Brandes | Aminoalkyl ethers of phenols as antiproliferative anticancer agents |
| US5798339A (en) * | 1990-12-17 | 1998-08-25 | University Of Manitoba | Treatment method for cancer |
| US5618846A (en) * | 1990-12-17 | 1997-04-08 | University Of Manitoba | Treatment method for cancer |
| ES2063574T3 (es) * | 1990-12-17 | 1995-01-01 | Univ Manitoba | Metodo de tratamiento mejorado para el cancer. |
| US6284799B1 (en) * | 1994-02-17 | 2001-09-04 | University Of Manitoba | Cancer treatment |
-
2002
- 2002-11-06 US US10/494,961 patent/US20050119263A1/en not_active Abandoned
- 2002-11-06 EP EP02774209A patent/EP1441711A1/en not_active Withdrawn
- 2002-11-06 CA CA002465916A patent/CA2465916A1/en not_active Abandoned
- 2002-11-06 WO PCT/CA2002/001725 patent/WO2003039526A1/en not_active Ceased
- 2002-11-06 JP JP2003541817A patent/JP2005512996A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023516291A5 (https=) | ||
| RU2508110C2 (ru) | КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek | |
| US20020165261A1 (en) | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders | |
| RU2008133654A (ru) | Способ и лекарственное средство для лечения тяжелой сердечной недостаточности | |
| JP2017125050A (ja) | 腫瘍転移および癌の治療 | |
| JP2006518731A5 (https=) | ||
| CA2555457A1 (en) | A novel therapeutic agent for amyotrophic lateral sclerosis (als) or diseases caused by als | |
| JP2005512996A5 (https=) | ||
| JP2005501825A5 (https=) | ||
| JP3007992B2 (ja) | （ｒ）−アムロジピンによる平滑筋細胞の遊走の抑制 | |
| RU2007104176A (ru) | Синтез и применение (-)-бета-элемена, (-)-бета-элеменала, (-)-бета-элеменола, фторида (-)-бета-элемена и их аналогов, а также промежуточных продуктов и композитов | |
| JP2002518506A5 (https=) | ||
| CA2376023A1 (en) | Therapeutic agents | |
| JP2006516532A5 (https=) | ||
| CA2482687A1 (en) | Treatment of mesothelioma | |
| RU2005110401A (ru) | Применение комбинаци dppe с другими химиотерапевтическими агентами для лечения рака молочной железы | |
| JPH09506902A (ja) | 前立線癌の化学療法剤の補助剤 | |
| RU2005109421A (ru) | Лечение метастатического рака молочной железы антрациклинами и таксанами | |
| JP2006516532A (ja) | 乳癌の新補助的処置 | |
| JP2006516533A5 (https=) | ||
| EP1485090A2 (en) | Combinations comprising epothilone derivatives and alkylating agents | |
| JPS6337767B2 (https=) | ||
| JP2008519808A5 (https=) | ||
| Young et al. | Benign paragangliomas | |
| WO2004022044A1 (en) | Use of a combination of a taxane with dppe for the treatment of cancer |